Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with active control (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists may leads to higher bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding ‐ clinically indicated non‐major Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Major bleedings · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower major bleedings (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of major bleeding · patients with venous thromboembolism
The intervention probably leads to higher incidence of major bleeding (moderate certainty).
1 finding from 1 review
Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).
1 finding from 1 review